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Developmental and epileptic encephalopathies are a heterogeneous group of early-onset epilepsy syndromes dramatically impairing
neurodevelopment. Modern genomic technologies have revealed a number of monogenic origins and opened the door to therapeut-
ic hopes. Here we describe a new syndromic developmental and epileptic encephalopathy caused by bi-allelic loss-of-function var-
iants in GAD1, as presented by 11 patients from six independent consanguineous families. Seizure onset occurred in the first 2
months of life in all patients. All 10 patients, from whom early disease history was available, presented with seizure onset in the
first month of life, mainly consisting of epileptic spasms or myoclonic seizures. Early EEG showed suppression-burst or pattern of
burst attenuation or hypsarrhythmia if only recorded in the post-neonatal period. Eight patients had joint contractures and/or pes
equinovarus. Seven patients presented a cleft palate and two also had an omphalocele, reproducing the phenotype of the knockout
Gad1–/– mouse model. Four patients died before 4 years of age. GAD1 encodes the glutamate decarboxylase enzyme GAD67, a
critical actor of the c-aminobutyric acid (GABA) metabolism as it catalyses the decarboxylation of glutamic acid to form GABA.
Our findings evoke a novel syndrome related to GAD67 deficiency, characterized by the unique association of developmental and
epileptic encephalopathies, cleft palate, joint contractures and/or omphalocele.
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Introduction
Proper function of the brain is governed by the dense net-
work of neuronal connections. Inhibitory interneurons play
a crucial role in controlling network activity. Glutamate
decarboxylase (GAD) catalyses the conversion of the excita-
tory neurotransmitter L-glutamic acid to c-aminobutyric
acid (GABA), the main inhibitory neurotransmitter in the
mammalian CNS. In vertebrates, GAD exists in two iso-
forms, GAD67 and GAD65, encoded by two independent
genes GAD1 and GAD2, respectively. While GAD67
(MIM#605363) is ubiquitously expressed and uniformly dis-
tributed throughout the neuron and preferentially synthe-
sizes cytoplasmic GABA (Dirkx et al., 1995; Laprade and
Soghomonian, 1995), GAD65 (MIM#138275) is localized
in nerve terminals and regulates the synthesis of GABA for
vesicular release (Soghomonian and Martin, 1998). GAD67,
the major isoform at embryonic stages (Asada et al., 1997;
Soghomonian and Martin, 1998), has an essential role in
neuronal development and synaptogenesis, as well as in nor-
mal development of the palate and foetal movements (Asada
et al., 1997; Oh et al., 2010).
The importance of GAD67 for neuronal and non-neuronal
development has been shown in different animal models.
Gad1–/– mice die at birth with cleft palate and hypoxia and
exhibit reduced levels of GABA in the cerebral cortex
(Asada et al., 1997; Condie et al., 1997). About half of
Gad1–/– mice also show omphalocele (Saito et al., 2010).
Their early mortality, however, precludes the evaluation of
any neurological phenotype. Homozygous knockdown of
gad1 in zebrafish also results in craniofacial defects and
early lethality (Zhang et al., 2017). However, a recent study
managed to bypass the early developmental stages through
the use of a photo-activatable morpholino oligonucleotide,
allowing zebrafish to develop normally. The animal showed
increased electrophysiological brain activity and behavioural
correlates of seizures in mutants (O’Connor et al., 2019).
In humans, GAD1 has been described as a susceptibility
gene for schizophrenia (Addington et al., 2005; Straub et al.,
2007; Zhao et al., 2007). The role of GAD1 with monogen-
ic disorders is, however, less well established. GAD1 has
been suggested as a candidate gene for autosomal recessive
spastic cerebral palsy (McHale et al., 1999), a permanent
non-progressive central motor dysfunction that affects
muscle tone, movement and posture, as a result from defects
in the developing CNS (Hughes and Newton, 1992;
Rosenbaum et al., 2007; Rosenbloom, 2007). Subsequently,
a homozygous missense variant in GAD1 leading to a
p.(Ser12Cys) substitution in GAD67, has been identified in a
single family with four affected siblings with autosomal re-
cessive cerebral palsy spastic quadriplegic type 1 (CPSQ1)
(MIM#603513) (Lynex et al., 2004). The clinical character-
istic included a spastic diplegia with mild hypertonia in the
arms, and moderate-to-severe intellectual disability. Two
affected siblings had flexion contractures at the knees. The
report did not mention any seizures, dysmorphic or non-
neurological features. However, no functional studies
were performed to validate this finding. In addition,
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non-syndromic cleft lip with or without cleft palate
(NSCLP), one of the most common craniofacial malforma-
tions, has been associated with GAD67 in the Japanese
population (Kanno et al., 2004).
Here, we report 11 affected individuals from six unrelated
families, with a severe neurodevelopmental phenotype con-
sisting of early-onset epilepsy, intellectual disability, cleft pal-
ate and a variable association of pes equinovarus,
arthrogryposis multiplex congenita, scoliosis and omphalo-
cele due to bi-allelic loss-of-function variants in GAD1.
Materials and methods
Patients and genetic analysis
Eleven patients from six unrelated families of Algerian (Family
A), Egyptian (Family B), Turkish (Families C and E), Iranian
(Family D) and Brazilian (Family F) origin were included in this
study (Fig. 1). The respective families were identified through
GeneMatcher (Sobreira et al., 2015). Written informed consent
for genetic testing and photographic material were obtained
from the parents or legal guardians. The study was conducted
in accordance with the Declaration of Helsinki and it was
approved by the relevant institutional review boards in
Netherlands, Iran, Egypt, Germany, Sweden, Turkey and Brazil.
Molecular genetic analyses were performed in different re-
search and diagnostic centres. Blood samples were obtained
from the patients, their parents and unaffected siblings in some
families. Whole-exome sequencing (WES) or whole-genome
sequencing (WGS) was performed on Patients A-III:1 and A-III:
2 from Family A, Patient B-IV:4 from Family B, Patients C-III:1
and C-III:2 and their parents (Subjects C-II:1 and C-II:2) from
Family C, Patient D-V:3 from Family D, Patient E-III:2 from
Family E and Patient F-IV:1 from Family F, independently.
Detailed genetic methods are provided in the Supplementary
material.
GAD1 variants identified in the patients and their family
members were validated by bidirectional Sanger sequencing, for
each family, independently. PCR primers are available on re-
quest. GAD1 transcript NM_000817.2 was used for variant
nomenclature.
Complementary DNA analysis in
Family A
To study the effect on splicing of the c.1414-1G4C GAD1
variant identified in Family A reverse transcription of RNA
extracted with the RNeasyV
R
Mini Kit (Qiagen) from Epstein-
Barr virus–immortalized lymphoblastoid cells of both parents
(Subjects A-II:1 and A-II:2) was performed using the ExpandTM
RT kit (Roche Applied Science), according to the manufacturer’s
protocol. A nested PCR approach was used to amplify exons 14
to 18 (primer sequences are available in the Supplementary ma-
terial). TOPO TA Cloning pCRTM2.1-TOPOV
R
vector kit
(Thermo Fischer Scientific) was used to separate the different
PCR products that were finally sequenced with a 3500 genetic
analyzer (Applied Biosystems).
Generation of p.Lys232del-GAD67
in cell-free protein expression assay
in Family B
Cell-free protein expression assay was performed to study the
impact of the c.695_697delAGA, p.(Lys232del) variant identi-
fied in Family B on expression levels of GAD67. The human
full-length wild-type GAD1 cDNA fragment (NM_000817.2)
was cloned into a pRSET-A express cloning vector followed by
introduction of the c.695_697delAGA variant by QuikChange
II (Agilent Technologies). Wild-type and mutant-GAD1 con-
structs were sequenced to verify the complete GAD67 coding se-
quence and correct introduction of the desired mutation.
Recombinant wild-type and p.Lys232del-GAD67 were
expressed from the constructs using EasyXpressTM Insect Cell
Protein Synthesis Kit (Invitrogen), according to the manufac-
turer’s protocol.
Immunoblot analysis of wild-type
and p.Lys232del-GAD67
Immunoblotting was performed using the N-terminally acety-
lated recombinant wild-type and p.Lys232del-GAD67 proteins.
Lysates were prepared as previously described (Olive et al.,
2015), run on 12% NuPAGEV
R
Bis-Tris gels and transferred
onto polyvinylidene difluoride (PVDF) membranes, using
a chromogenic western blot immunodetection kit,
WesternBreezeTM (Invitrogen), according to the manufacturer’s
instructions. The blot was probed with the primary antibodies
(anti-GAD67, 1:1000) (Sigma-Aldrich) overnight at 4C.
Missense variant 3D modelling
GAD67 protein modelling and prediction of the effects of the
p.(Glu509Lys) variant were generated using bioinformatic tools
from HOPE (Venselaar et al., 2010). The model was generated
based on a homologous structure of yeast GAD67 (PDB ID:
2OKJ) and built using the Yasara/WHAT IF Twinset. Structural
information was collected using information from WHAT IF
Web services, the UniProt database and the Reprof software.
Data availability
The authors confirm that the data supporting the findings of
this study are available within the article and its Supplementary
material.
Results
Clinical characteristics of affected
individuals
Case reports are summarized in Table 1, and extensively
described below. All patients were born to consanguineous
parents, either first or second cousins (Fig. 1). At the time of
report, four affected individuals had died. One of these four
patients (Case 10, Patient E-III:1) died at the age of 9 days
after a preterm birth at 29 weeks, before full phenotypic
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development could be evaluated. One patient (Case 1,
Patient A-III:1) was only first examined at the age of 6
months. The remaining patients all had neonatal develop-
mental and epileptic encephalopathies (DEE) with seizure
onset in the first months of life. No ictal EEG recordings
were available for re-evaluation in the context of this study.
Therefore, seizure classification was based on description of
seizures in medical records. Accordingly, seizure types at
onset mainly included myoclonic seizures (n = 5), or epileptic
spasms (n = 6). Both siblings of Family B presented with epi-
leptic spasms and ‘eyelid twitches’. Potentially the latter
were myoclonic seizures too. EEG at onset showed
Figure 1 Pedigrees of the families with GAD1 variants. Pedigrees of Families A–F. In the pedigree, squares = males; circles = females;
open symbols = unaffected family members; slash = deceased. Index cases (arrows) and family members who were analysed by next generation
sequencing (asterisks) are indicated. WES was performed for Families A, B, E and F and WGS for Families C and D. The grey symbols in the pedi-
gree C indicate adult-onset epilepsy without intellectual disability in two family members. Affected individuals are represented with black shaded
symbols. The GAD1 variants identified in each family are indicated.
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suppression-burst or variant with interburst attenuation pat-
tern (Case 8, Patient D-V:3) in seven of eight patients who
had recordings during the neonatal period, and hypsarrhyth-
mia in two patients who only had a first EEG taken later in
disease course. Seizures were eventually controlled by anti-
epileptic drugs in six patients, and were controlled for long
periods after addition of vigabatrin in five of them. Head cir-
cumference was in the normal range for all patients but one.
All living patients had severe psychomotor delay. Brain
MRI, when performed, was normal in five patients. One pa-
tient presented with hypoplastic corpus callosum and mild-
to-moderate dilated subarachnoid spaces, predominating on
left hemisphere and mild enlarged lateral ventricles (Case 3,
Patient B-IV:4). One patient had a posterior cervical junction
(Case 8, Patient D-V:3). Another had an atlanto-axial anom-
aly with minimal hydrocephalus at 2 months of age (Case 9,
Patient E-III:2). In one patient, MRI was normal at the age
of 4 months and showed mild cerebral atrophy with ven-
tricular enlargement at 6 years of age (Case 11, Patient F-
IV:1). Interestingly, in addition to neurological features,
seven patients presented a cleft palate, six joint contractures
and five pes equinovarus. Scoliosis was reported in four
patients. Both patients from Family B presented omphalo-
cele, and three patients were presenting facial dysmorphic
features without clear common elements (Fig. 2).
Case reports
Family A
Case 1: Patient A-III:1
Case 1 was a 6-year-old male, the first child of healthy first
cousin parents of Algerian origin (Fig. 1A). There was no
family history of epilepsy, intellectual disability or other neu-
rodevelopmental disorders. The patient was born at term
(40 weeks of gestation). Birth weight was 3.660 kg (mean),
height was 48 cm [–1 standard deviation (SD)] and head cir-
cumference 34 cm (–1 SD). Examination at birth showed
cleft soft palate with surgical correction at 2 months.
When first referred to the neuropaediatric unit, at 5
months of age, the patient had developmental regression
with loss of visual contact, abnormal neurological examin-
ation with opisthotonous and axial hypotonia. Weight and
height were at mean and head circumference at + 2 SD.
EEG showed hypsarrhythmia with brief episodes of voltage
attenuation without clear clinical correlate (Fig. 3A). Brain
MRI was normal. Metabolic screening was normal in blood,
urine and CSF (including amino acid chromatography, or-
ganic acid chromatography, acylcarnitine, lactate and pyru-
vate, neurotransmitters). The child was treated with
vigabatrin and was lost to follow-up and rehabilitations for
the following 2 years.
At 2 years and 6 months of age, he presented with spastic
quadriparesis, right plagiocephaly, poor visual contact, but
had the ability to smile. EEG still showed hypsarrhythmia
with clinically subtle spasms. Brain MRI, including spectros-
copy, was normal.
At last follow-up, at 6 years of age, the patient was not
able to sit unassisted, had spastic tetraparesis with limited
extension of knees and elbows, and showed no verbal com-
munication. The last EEG showed low-voltage and slow
background activity with multifocal low amplitude spikes.
No seizures were recorded.
Case 2: Patient A-III:2
Case 2 was a 2.5-year-old female, second affected offspring
in Family A, who was born at 37 weeks of gestation
(Fig. 1A). Birth weight was 3.190 kg (mean), height was 48
cm (mean) and head circumference 34.7 cm (mean). She had
a cleft soft palate. The patient was admitted at 2 days of age
to neonatal intensive care unit due to episodes with eye re-
vulsion, cyanosis and spasms-like movements. EEG showed
a suppression-burst pattern (Fig. 3B and C). She was treated
with levetiracetam and vitamins (B1, B6 and biotin).
Vigabatrin was added at 1 month because of persistence of
spasms. The combination of levetiracetam and vigabatrin
lead to seizure control at the age of 3 months. She had surgi-
cal correction of cleft soft palate at 10 months of age. At
last follow-up at 26 months of age, she had severe develop-
mental delay with axial hypotonia and absence of head con-
trol, segmental hypertonia with limited extension of knees
and, no visual contact with abnormal eye movements and
no verbal communication. EEG showed normal background
activity without epileptic abnormalities.
Family B
Case 3: Patient B-IV:4
Case 3 was a female, the third child of apparently healthy
first-cousin parents of Egyptian origin (Fig. 1B). She was a
product of in vitro fertilization (IVF) and pregnancy was
complicated by polyhydramnios. Prenatally detailed scan
revealed a liver containing omphalocele, intestinal atresia
and right talipes equinovarus. Delivery was at term by cae-
sarean section, and birthweight was 2.900 kg. Examination
at birth showed omphalocele and cleft soft palate. A sub-
cutaneous branchial fistula was noted at the left side of the
neck that spontaneously obliterated before 6 months of age
(Fig. 2B). Resection anastomosis was performed at 2 days of
age for correction of omphalocele and jejunal atresia
(Fig. 2). The patient was admitted to the neonatal intensive
care unit for 2 weeks. Seizures were first noted at 2 weeks of
age in the form of eye twitches and epileptic spasms. She
was treated with phenobarbital, valproic acid, oxcarbaze-
pine, and eventually became seizure-free with vigabatrin at
the age of 9 months. At follow-up at 9 months of age, the
patient was severely developmentally delayed with no head
support. At 2 years of age, she could not sit independently
and was unable to talk.
The patient presented with multiple congenital anomalies
and dysmorphias: plagiocephaly with bitemporal narrowing
and a forehead naevus flammeus, frontal upsweep and facial
hirsutism were noted. Further, she showed mid-face hypo-
plasia, facial asymmetry, and microretrognathia. The eyes
had bluish sclera, large cornea, squint and hypertelorism
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Figure 2 Clinical features of the patients. (A–G) Case 4 (Patient B-IV:4). (A) Total view of the proband at the age of 9 months, showing
multiple contractures at different joints, and corrected omphalocele. (B) Haemangiomas at the right ear and scalp. (C) Dysmorphic facial features
of the index patient, at the age of 2 years. Note hypertelorism, downslanting palpebral fissure, broad nasal bridge with anteverted nares, smooth
philtrum and thin upper lip vermilion. (D and E) Lateral view of the patient. Note flat facies, microretrognathia and abnormal asymmetric shaped
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were present, as well as wide downslanting palpebral fissure
and infraorbital creases. Eyebrows were broad and flared.
She had broad depressed nasal bridge, broad nasal ridge
and tip with enlarged anteverted nares, wide nasal base in
addition to smooth long philtrum. She had abnormal shaped
ears with low setting, over folding of the helix, prominent
inferior crus of antihelix, serpiginous and prominent stem of
antihelix, prominent antitragus and narrow external audi-
tory meatus. The ears were asymmetric with the serpiginous
prominent helix crus in the left ear and crumpled helix in
the right. The oral region showed absent cupid’s bow with a
thin upper lip vermilion, thick lower lip vermilion, under-
developed nasolabial fold and limited opening of mouth cav-
ity. Delayed teeth eruption was noted with only two lower
central incisors. The palate was high arched with small cleft
in the soft palate (Fig. 2). Multiple skin hemangiomas were
noted at the right eyelid, right ear and scalp. She had a short
neck, with anterior webbing. The shoulders were sloping
and narrow, and axillary webbing was noted. Limbs exhib-
ited a limited range of movement in all joints, with limited
extension of elbows and knees, talipes equinovarus or club-
foot of the right foot, ulnar deviation at the wrist and skin
dimples at the dorsal aspects of both elbows and wrists
(Fig. 2). She had small hands. All fingers were broad with
camptodactyly, short distal phalanges, prominent digital
pads, and shallow/absent flexion creases in plantar and dor-
sal surfaces. Thumbs were adducted bilaterally. Both feet
had rocker bottom appearance. The thorax was short with
hypoplastic widely spaced nipples and corrected omphalo-
cele was noted at the anterior abdominal wall with incision-
al hernia. She also had scoliosis. Examination of the
genitalia revealed large clitoris with hypoplastic labia minora
and majora (Fig. 2). Head circumference was within the nor-
mal range, while the weight and length were far below nor-
mal values for her age (53rd centile). The patient died at
the age of 2 years, from failure to thrive and respiratory
infection.
EEG showed a suppression-burst pattern at onset, evolv-
ing to hypsarrhythmia on recording at the age of 6 months.
Brain MRI at 1 month of age and at the age of 2 years
revealed hypoplastic corpus callosum, mainly of the body
and to a lesser degree of the genu and dilated subarachnoid
spaces predominating on left hemisphere and mildly
enlarged lateral ventricles (Fig. 4A–D). Ultrasonography of
the abdomen and pelvis was unremarkable and karyotype
was 46, XX.
Case 4: Patient B-IV:1
Case 4 was a similarly affected brother, who passed away at
the age of 4 years due to pulmonary infection and severe
growth retardation. He was delivered by elective caesarean
section at term with average birth weight (50th centile). At
birth, omphalocele and bilateral talipes equinovarus were
observed. He was admitted to neonatal intensive care unit
for 3 weeks due to pulmonary infection, followed by surgi-
cal repair of the omphalocele. He also had failure to thrive,
seizures, arthrogryposis and global developmental delay.
Seizures were first noted at 2 weeks of age in the form of
eye twitches and epileptic spasms. He was treated with
phenobarbital, valproic acid and eventually became seizure-
free with vigabatrin at the age of 2 years. He presented mul-
tiple congenital anomalies and dysmorphias similar to his
sister. His body weight at 4 years of age was 5 kg (far below
3rd centile).
Family C
Case 5: Patient C-III:1
Case 5 was a 12-year-old female, the first child of an appar-
ently healthy first-cousin Turkish couple (Fig. 1C). She had
an onset of eyelid-myoclonia at the age of 2 weeks, and 1
week later also showed myoclonic seizures of the upper
limbs. At the age of 5 months, she developed generalized
tonic-clonic seizures. The patient was initially treated with
vitamin B6 and B12, and later with topiramate, phenobar-
bital, levetiracetam, zonisamide, valproate, azetazolamide,
lamotrigine and vigabatrine without any effect of seizure fre-
quency. Currently, she suffers from a refractory epilepsy
with bursts of myoclonic seizures (once a month) and tonic-
clonic seizures (once a week) despite treatment with levetira-
cetam and diazepam. Initial EEG in the second week of life
showed a suppression-burst pattern. Later EEGs showed
multifocal spike wave complexes with a generalized and
focal slowing with shifting maxima. In the EEG at the age of
7 years, photosensitivity was observed at frequencies from 1
to 6 Hz in the form of generalized sharp waves, and at 7 to
10 Hz in the form of occipital sharp wave. Brain MRI at the
age of 3 years and 1 month was normal, as was neurometa-
bolic screening. She developed a profound intellectual dis-
ability, with absence of expressive and receptive speech,
Figure 2 Continued
ears. (F) Total view of the proband showing multiple contractures at different joints, right talipes equinovarus (TEV) and corrected omphalocele
with incisional hernia. (G) Abnormal external genitalia with hyperplastic clitoris and hypoplasia of both labia majora and minora. (H) Frontal view
of Case 7 (Patient D-V:2) showing low set ears, broad nasal bridge, mild hypertelorism and thin upper lip. (I–O) Cases 9 and 10 (Patients E-III:2
and E-III:1). Photographs of Patient E-III:2 at the age of 3.5 months (I and J) and 15 months (K–N). (I, J, M and N) Note facial dysmorphism (high
arched eyebrows, up-slanting palpebral fissures, hypertelorism, depressed nasal bridge, anteverted nares, low set ears, microretrognathia, long
philtrum, sparse eyebrows and hair). (I–J) Cervical and axillar web. (J) Abdominal distension. (K–N) Flexion contractures of extremities and (L)
pes equinovarus deformity. (O) Case 10 (Patient E-III:1). Note prematurity (born at 29 weeks age of gestation), hypertelorism, macrocephaly,
narrow thorax and short limbs.
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Figure 3 Interictal EEGs. (A) Case 1 (Patient A-III:1). Hypsarrhythmia at the age of 5 months; note random high amplitude slow waves and
spikes during sleep with episodes of voltage attenuation. (B and C). Case 2 (Patient A-III:2). (B) Suppression-burst pattern (S-B) persists at the
age of 5 weeks (42 weeks age of gestation). Note bursts of high-voltage slow waves intermixed with high amplitude spikes, polyspikes and fast
rhythms, lasting 4–5 s and alternating with complete suppression lasting 4–5 s in wakefulness. Some bursts could terminate with slow waves
mixed up with rare sharp waves predominating over central regions. Note also brief and rare bursts of moderate amplitude theta/delta waves.
(C) Longer interburst interval (8–10 s) in sleep.
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absence of head control, and no fixation of objects. First
available neurological exam at the age of 5 months showed
a generalized hypotonia with some limited movements of all
limbs. At the age of 2 years there was a regression evolving
to a complete tetraparesis, with generalized increased muscle
tonus without clear pyramidal signs, and pes equinus. She
has a palatine cleft, a talipes on the left side and a conduct-
ive hearing loss. She suffers from recurrent fever episodes
without any signs of infection. No further facial dysmorphic
signs were observed.
Case 6: Patient C-III:2
Case 6 was the second child of Family C (Fig. 1C). He
showed a similar phenotype as his older sister (Patient C-
III:1), with refractory epilepsy with myoclonic, tonic and
tonic-clonic seizures, from the first day of life. As his sister,
he had a palatine cleft. Neonatal EEGs showed a suppres-
sion-burst pattern and brain MRI was normal.
Neurometabolic screening was normal. Seizures deteriorated
under ketogenic diet and he died from refractory seizures at
the age of 2 years. At that time, he had a profound intellec-
tual disability with tetraparesis with increased muscle tonus.
There was a familial history of seizures, as the paternal
grandfather (Subject C-I:1) had two tonic-clonic seizures at
the age of 40 and 47 years, and the maternal grandfather
(Subject C-I:3) had tonic-clonic seizures arising from sleep
since the age of 40 years. There was no information on EEG
or MRI available.
Family D
Case 7: Patient D-V:2
Case 7 was a 10-year-old male, the second child of healthy
second-cousin parents from Iran with a family history of epi-
lepsy and development delay (Figs 1D and 2J). He was deliv-
ered at 37 weeks of gestation by caesarean section. First
myoclonic seizures were noted within 1 day after birth and
EEG showed dysrhythmia. The seizures evolved into epilep-
tic spasms. The patient was treated with clonazepam, primi-
done and vitamin B6 under which he remained seizure-free
from the age of 10 years until the most recent follow-up
examination at 11 years of age. His neurodevelopment was
profoundly delayed with no ability to walk. However, brain
MRI indicated prominent inner liquor spaces without overt
brain malformations (Fig. 4E). He initially showed reduced
muscle tone and developed spasticity and dystonia as well as
scoliosis later during the disease course.
Case 8: Patient D-V:3
Case 8 was a 2-month-old female, the third child of Family
D (Fig. 1D), delivered at 38 weeks of gestation by caesarean
section. She was noted to suffer from epileptic spasms and
myoclonic seizures at 7 days of age. EEG showed burst at-
tenuation initially and scattered sharp waves later during the
disease course. Nitrazepam, phenorbarbital and vitamin B6
resulted in a seizure-free episode of 2 months. At follow-up
at 15 months of age, she was able to roll over onto her sides
but was unable to sit unsupported. Head circumference at
15 months of age was 44 cm (1.2 cm 53rd centile). Brain
MRI at the age of 10 years did not reveal any structural
defects except a cervical junction notch with impression on
the spinal cord (Fig. 4F and G).
Family E
Case 9: Patient E-III:2
Case 9, the proband from Family E, was the second child of
first-cousin parents. He was referred to Istanbul University
Cerrahpasa Medical Faculty, Pediatric Genetic Department
at 2 months of age due to facial dysmorphism, development
Figure 4 Brain MRI. (A–D) Case 3 (Patient B-IV:4). Sagittal T1
and T2 cuts through the midline at the age of 1 month (A) and 2
years (B) showing hypoplastic corpus callosum, mainly body and to
a lesser degree its genu, progressive cerebellar and cerebral atrophy
and a cervical notch. Axial cuts T1 (C) and T2 (D) at the age of 2
years demonstrating mild-to-moderate cortical atrophy predomi-
nating on left hemisphere and mildly enlarged lateral ventricles.
(E–G) Cases 7 and 8 (Patients D-V:2 and D-V:3). (E) Sagittal
MRI image of Case 7 (Patient D-V:2) showing prominent inner li-
quor spaces without overt brain malformations. (F) Sagittal MRI
image of Case 8 (Patient D-V:3) showing prominent inner liquor
spaces without apparent brain malformations except a cervical
notch causing an impression in the upper cervical spinal cord area.
(G) Normal cerebellar size is demonstrated in Case 8 (Patient
D-V: 3).
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delay, cleft palate, Hirschsprung disease, and pes equinova-
rus deformity (Fig. 2). Intrauterine hydrocephalus was diag-
nosed in the third trimester of pregnancy. The patient was
delivered at 37 weeks of gestation by caesarean section. The
birth weight and length were 3.410 kg and 45 cm, respect-
ively. He was followed-up in the neonatal intensive care unit
for 27 days because of respiratory distress, cleft palate and
abdominal distension. Intestinal obstruction was suspected
during neonatal intensive care unit follow-up. Double con-
trast barium enema demonstrated colonic dilatation. The
diagnosis of Hirschsprung was confirmed by rectal biopsy.
Initial physical examination of the proband revealed fa-
cial dysmorphism (high arched eyebrows, upslanting pal-
pebral fissures, hypertelorism, depressed nasal bridge,
anteverted nares, long philtrum, thin lips, low-set ears,
auricular pit, microretrognathia), cleft palate, cervical and
axillar webbing, flexion contractures of elbows and knees,
abdominal distension, rectus diastasis, umbilical hernia, 3-
cm palpable liver below costal margin, hirsutism of back,
hypotonia and pes equinovarus deformity (Fig. 2).
Epileptic spasms were observed during physical examin-
ation. Retrospectively these were present from 1 month of
age, but were not recognized as seizures by parents. EEG
revealed hypsarrhythmia. Phenobarbital, vigabatrin and
vitamin B6 were started as initial treatment. Brain CT scan
at 2 months of age demonstrated minimal hydrocephalus
and atlantoaxial anomaly. Although epileptic spasms were
well controlled with antiepileptic treatment, hypsarrhyth-
mia was still present in the control EEG, at 6 months of
age. On eye examination, nystagmus, alternating esotro-
pia, and bilateral pale optics disk were observed.
Audiogram was normal at birth, but he failed the hearing
test performed at 1 year of age.
In the follow-up, the patient had severe recurrent aspir-
ation pneumonia requiring hospitalization and oxygen treat-
ment. Chest CT revealed bilateral atelectasis, fibrotic
changes and decrease in right lung volume, due to the intra-
thoracic placement of the right liver lobe. Evaluation for dia-
phragmatic hernia was normal. Barium oesophagogram
showed nasal regurgitation and laryngotracheal aspiration,
requiring nasogastric tube feeding.
Echocardiography showed a small patent foramen ovale,
small atrial septum defect (both resolved in control echocar-
diography), focal septal hypertrophy, and urinary ultrason-
ography revealed grade 1 nephrocalcinosis.
At last examination, at 15 months of age, the patient did
not have head control or eye contact. His weight, length,
and head circumference were 8.800 kg (3–10th centile),
67 cm (53rd centile) and 48.5 cm (50–97th centile), respect-
ively. He showed a large anterior fontanelle (4  3 cm),
sparse hair and eyebrows, and 5 cm palpable liver below the
costal margin. He had axial hypotonia and spasticity of the
limbs. Persistence of flexion contractures of knees and
elbows, and ulnar deviation of the wrist were observed. The
hirsutism of the back was no more observed at the last
examination.
Case 10: Patient E-III:1
Case 10 (Patient E-III:1), the first child of the parents of pro-
band Case 9, was born at 29 weeks of gestation, had cleft
palate, short neck, narrow thorax, myoclonic seizures, con-
genital heart disease (large patent ductus arteriosus, small
atrial septum defect moderate pulmonary hypertension), ab-
dominal distension and pes equinovarus deformity similar to
the proband, and died at postnatal Day 9 due to sepsis
(Fig. 2).
Family F
Case 11: Patient F-IV:1
Case 11 was a 7-year-old female, the first child of healthy
first-cousin Brazilian parents of Caucasian and African an-
cestry. There was no family history of any developmental
disorder or epilepsy. Pregnancy was uneventful and she was
delivered after 37 weeks of gestation by caesarean section.
Her physical examination was normal at birth and she was
discharged at 3 days of age, apparently in good health
condition.
At 7 days of age, the family recognized abnormal fast fa-
cial twitches with blinking followed by staring. She was eval-
uated by a child neurologist and was treated initially with
phenobarbital and 1 month later with valproic acid, without
success. EEG was abnormal with multifocal discharges and
periods of suppression-burst. Epilepsy remained uncon-
trolled, with several daily seizures (focal, epileptic spasms
and star gazing). At 10 months of age, clobazam was intro-
duced as an add-on drug without improvement, as she still
had daily seizures. Finally, at 11 months of age she started
vigabatrin (max dose of 1000 mg), which completely con-
trolled the seizures after 2 weeks later. Vigabatrin was con-
tinued for 2 years. The patient is currently receiving
lamotrigine (100 mg/day), levetiracetam (750 mg/day), and
clobazam (10 mg/day), with the occasional seizure. Several
follow-up EEGs demonstrated multifocal epileptiform activ-
ity, sometimes more intense in the centrotemporal region.
Additional tests included two brain MRIs, showing mild
cerebral atrophy at 13 months of age with ventricular dila-
tion at the age of 6 years. Metabolic work-up was normal.
She has been in a continuous rehabilitation programme,
which includes physical, occupational and speech therapy,
from the age of 3 months.
At last examination, at 6 years of age, her weight was
17 kg, occipital frontal circumference 50 cm with positional
plagiocephaly, inverted nipples, hirsutism and severe scoli-
osis. No dysmorphic facial features were seen. Neurological
examination disclosed a profound developmental delay/intel-
lectual disability. She had good eye contact and showed
interest in watching cartoons and turned her face to sounds.
She had incomplete head support. She was able to roll over
on her back but could not sit, even with support. The pa-
tient did not follow commands or speak a single meaningful
word. She kept her hands fisted with flexion of wrists and
her arms movements were uncoordinated and choreathe-
totic. She could not grasp objects. Muscle tonus in the upper
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limbs was variable with hypo- or hypertonia and her lower
limbs were spastic with brisk reflexes and Babinski sign.
Genetic findings
Familial genotyping results and identified GAD1 variants
are summarized in Fig. 1 and Supplementary Fig. 1. After
stringent filtering of WES or WGS data, rare homozygous
bi-allelic variants in GAD1 were retained as the only likely
pathogenic variant in all affected individuals (Supplementary
Fig. 1). In all families, Sanger sequencing confirmed segrega-
tion of the GAD1 variants with the disease phenotype
(Supplementary Fig. 1) and a recessive mode of inheritance
associated with the disease. Detailed genetic results are pro-
vided in the Supplementary material.
Four of six families carried a homozygous variant pre-
dicted to truncate the protein (Families A, C, D and E). The
c.1414-1G4C variant in Family A was predicted to abolish
the acceptor splice-site of GAD1 exon 15 by in silico splic-
ing programmes (MaxEntScan and GeneSplicer). cDNA ana-
lysis confirmed the absence of normal mRNA product with
three aberrant isoforms: one with exon 15 skipped, one with
76 bases of intron 14 retained and one with the first seven
bases of exon 15 deleted.
In Family C, a homozygous 5-bp deletion, c.812_816
delTTAAG, leading to a frameshift p.(Val271Aspfs*9) was
identified (Fig. 1C and Supplementary Fig. 1C). Families D
and E, of Persian and Turkish origin, respectively, shared the
same GAD1 c.1591C4T variant leading to a premature stop
codon p.(Arg531*) (Fig. 1D and E and Supplementary Fig. 1D
and E). Given the relative geographical proximity, a common
haplotype is possible.
The proband of Family B carried a novel homozygous 3-
bp deletion in exon 7, c.695_697delAGA (Fig. 1B and
Supplementary Fig. 1B), leading to the deletion of a highly
conserved lysine at position 232, p.(Lys232del)
(Supplementary Fig. 2A). The variant is not present in any
public databases [1000 Genome Project Database, Greater
Middle East (GME), ExAC/GnomAD browsers]. In silico
prediction programme predicts the p.(Lys232del) variant to
be disease-causing (MutationTaster). In addition, SpliceAid2
predicts that the 3-bp AGA at position c.695_697 of GAD1
mRNA is part of consensus binding sequences for seven dif-
ferent splicing factors. Consequently, c.695_697delAGA is
predicted to result in a splice site loss, leading to a frameshift
and subsequently to a premature termination codon.
Because of the lack of autopsy material from the deceased
affected siblings, in vitro protein expression of wild-type and
mutated GAD67 was studied, using an Escherichia coli cell-
free expression system. Western blotting of wild-type and
p.Lys232del-GAD67, however, revealed that p.Lys232del-
GAD67 was expressed at a comparable level as wild-type-
GAD67, which is not in favour of an effect on splicing
(Supplementary Fig. 3).
In Family F, another homozygous missense variant
was identified, p.(Glu509Lys) (Supplementary Fig. 1F),
which is absent from the gnomAD database. It is predicted
pathogenic by DANN, GERP, LRT, MutationAssessor,
MutationTaster and PROVEAN prediction scores as it
affects an evolutionarily extremely well-conserved residue
(Supplementary Fig. 2B) within the pyridoxal-dependent de-
carboxylase conserved domain, indicating that the variant
may damage protein function. The HOPE bioinformatics
resources were applied to generate a GAD67 structural
model and to predict the effects of the missense allele
(Supplementary Fig. 4). The wild-type glutamate residue is
predicted to form salt bridges with the arginine at position
316, the lysine at position 318 and the lysine at position
389. These ionic interactions will likely be disturbed in the
mutated protein as the wild-type amino acid glutamate is
negatively charged, while the mutated amino acid, lysine, is
positively charged with a larger side chain. Further reversal
of charge further may cause repulsion between residues in
the protein core and because of the larger side chain, the
mutated amino acid is predicted to no longer fit into the do-
main core.
Discussion
We describe 11 patients, from six independent families, pre-
senting early-onset DEE and a variable association of cleft
palate, omphalocele, equinovarus and/or more widely dis-
tributed joint contractures, caused by bi-allelic variants of
GAD1. Four of six families carried a homozygous variant
leading to a truncated protein (Supplementary Fig. 5), sup-
portive of a complete loss-of-function mechanism. GAD1
constraint scores calculated on the gnomAD dataset are
also in line with an autosomal recessive inheritance of loss-
of-function variants, as the pRec score (Lek et al., 2016)
(probability of being intolerant to bi-allelic loss-of-function
variants) is 0.934, above the 0.9 threshold to consider a
gene intolerant to bi-allelic variants.
In addition to nonsense and frameshift variants, we
found one deletion of a highly conserved lysine [c.695_697
delAGA, p.(Lys232del), in Family B]. In silico predictions
were also in favour of a splicing effect. We could not prove
an effect of this in-frame deletion on the expression level of
GAD67. However, the normal result of the cell-free expres-
sion assay (used in the absence of tissue of the deceased sib-
lings) does not exclude a potentially deleterious impact of
the variant on pre-mRNA splicing, as suggested by in silico
prediction programmes, as the assay begins from mature
GAD1 cDNA sequence, bypassing splicing events. The re-
capitulation of the knockout mouse model phenotype (co-
occurrence of cleft palate and omphalocele) in this family,
together with phenotypic similarities with the remaining
families, is strongly supportive of pathogenicity of this vari-
ant, while loss of function could not be formally
demonstrated.
A remarkably increased muscle tone was a core clinical
feature seen in all patients. An increase in muscle tone is also
the hallmark feature of stiff person syndrome, a disorder
linked to anti-GAD antibodies. This autoimmune disorder is
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thought to result in an impairment of spinal and supra-
spinal inhibitory neurons, leading to excessive excitatory
drive upon the motor neurons. Whereas in stiff person syn-
drome axial muscles are predominantly affected, patients
reported in our manuscript often had axial hypotonia. This
most likely reflects the detrimental impact of a constitutive
GABA deficiency on neurodevelopment. Indeed, given the
pivotal role of GABA as an inhibitory neurotransmitter and
its role in the development of the nervous system, the associ-
ation of GAD1 loss-of-function mutations with DEE is not
unexpected. De novo mutations in several GABA receptor
genes have previously been described to lead to DEE (Epi4K
Consortium et al., 2013; Hamdan et al., 2017; Moller et al.,
2017). Notably, loss-of-function variants in GABRA3,
encoding the a3-subunit of the GABAA receptor, have been
associated with a DEE including dysmorphic features and a
cleft lip (Niturad et al., 2017). In addition, GABA appears
to be essential for foetal movement, as well as developmental
processes that depend on foetal movements (Saito et al.,
2010; Kakizaki et al., 2015). Several studies demonstrated
that both the cleft palate and the omphalocele seen in
Gad1–/– mice are the consequence of reduced foetal move-
ments (Laprade and Soghomonian, 1995; Iseki et al., 2007;
Saito et al., 2010; Kakizaki et al., 2015). Further studies
demonstrated that the presence of cleft palate is due to a de-
fect of foetal oral movement of the tongue during palatal de-
velopment and Gad1 is specifically required in the CNS for
normal palatal formation (Iseki et al., 2007; Oh et al.,
2010). Furthermore, it has been suggested that lack of
tongue movement may result in a tongue position enhancing
cleft formation, such as tongue positioning in-between the
two palate shelves, as observed in a recent prenatal MRI
study for Robin syndrome patients with clefts (Resnick
et al., 2018). Likewise, it has been suggested that movement
reduction leads to a hunched posture in the foetus and
increased intra-abdominal pressure, resulting in failure of
retracting umbilical hernia and omphalocele (Saito et al.,
2010; Kakizaki et al., 2015). Also the pes equinovarus, joint
contractures and arthrogryposis, seen in several of the
patients in our study, are known to reflect a reduction of
foetal movements (Hall, 1997). As such, the non-neural phe-
notypes seen in our cohort of patients should probably be
seen as secondary to the severe CNS involvement.
Despite identical mutation in Families D and E, there was
some phenotypic variability between both families; in par-
ticular there was an absence of pes equinovarus, joint con-
tractures and cleft lip in Family D. This might be influenced
by variability in genetic backgrounds or environmental fac-
tors that modulate movement in utero. The cervical notch
observed in the brain MRI of the proband of Family D is
likely unrelated to the GAD1 variant as no other cases in
our cohort displayed a similar finding. Also, in Family C,
both paternal and maternal grandfather had late onset epi-
lepsy. Epilepsy type and disease course were, however, total-
ly different from probands, and we thus do not assume that
they are caused by the same genetic defect. However, we
cannot exclude that other epilepsy susceptibility variants
segregate in the family and possibly might influence the pro-
bands’ phenotype.
Finally, a remarkably good response of seizures to vigaba-
trin was seen in five of seven individuals who were treated
with the drug. Vigabatrin inhibits the GABA transaminase,
responsible for GABA catabolism, thus increasing the synap-
tic concentration of GABA reduced by GAD1 variants. It
should be noted however, that this good response seems to
be driven by seizure semiology, as particularly patients with
epileptic spasms appeared to benefit from vigabatrin.
Vigabatrin is the standard treatment choice for epileptic
spasms, a seizure type that is known to respond well to this
drug regardless of underlying aetiology. Also, given the im-
portance of GABA in prenatal neurodevelopment, it remains
to be demonstrated whether postnatal treatment initiation
still has an impact on intellectual functioning, and whether
this exceeds the expected beneficial effect of a reduction of
seizure burden on neurodevelopment. Nevertheless, this ob-
servation should be an incentive to validate the role of viga-
batrin as a targeted (seizure) treatment for GAD1-related
disorder. Several examples of the usefulness of ultra-fast gen-
omic sequencing for medical management have been
reported (Smith et al., 2015; Friedman et al., 2019). Given
the early-onset of seizures and the potential importance of
early treatment initiation, we thus strongly advocate early
clinical genomic sequencing in patients with early-onset
seizures.
In conclusion, our study provides evidence of the essential
role of the GAD67 enzyme during human foetal develop-
ment. Bi-allelic loss-of-function variants in humans fully re-
capitulate the association of epilepsy, cleft palate and
omphalocele observed in animal models. Moreover, we em-
phasize the importance of early genetic testing to drive thera-
peutic decisions for DEE.
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